Investec Asset Management has taken a 7.05 per cent stake in Epistem, a biotech firm working in the area of personalised medicine.
Over the past three months the loss-making AIM-listed company, Epistem, has shot up approximately 50%.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Total sales of £5.6m (2011: £5.8m) were driven by a solid performance by Contract Research Services and strong growth in its Personalised Medicine division. The latter delivered more than 100% year-on-year growth, following collaborations with GlaxoSmithKline, Sanofi-Aventis and emerging sales of its Genedrive diagnosis machine.
There has been ongoing investment in its Novel Therapies lead programme and its Diagnostics (Genedrive) programmes. This was the reason it gives for moving into a pre-tax loss of £720,000 from a profit of £357,000.
A successful £2.7m cash placing, led to a strengthened cash balance of £4.7m at June 30th.
Consensus forecasts for the year ending June 30th 2013 are for a pre-tax loss of £270,000 on turnover of £6.98m.
CM
-
Scammers steal over £600 million from Brits - how to protect yourselfFraud cases in the first half of the year surged by 17% compared to the same period in 2024. Is your money at risk?
-
Financial support for carers: what can you get?Unpaid carers miss out on an average £6,400 a year in annual salary by cutting work to support loved ones. We explore benefits that can plug the financial gap.
